HI-6 Dimethanesulfonate (DMS) and Atropine Sulfate Reconstitution Autoinjector Device (RAD) Feasibility Assessment
Purchaser
Department of National Defence (DND)
Country
Canada
Notice published
2 Jun 2026
Tenqual indexed
3 Jun 2026
Closing date
16 Jun 2026
Source ID
Docs found
—
Save this notice and create a free tender alert for similar public opportunities.
- Create one free tender alert.
- See a short explanation of why each tender matches.
- Upgrade later when you want help planning and writing the bid.
Tender summary
The Department of National Defence (DND), specifically the Canadian Forces Health Services (CFHS), has a requirement for the services of a Contractor to test and evaluate the feasibility of manufacturing HI-6 DMS and atropine sulfate drug products in a reconstitution autoinjector device (RAD). The scope of this requirement is to conduct a feasibility assessment using an existing prototype of a RAD with the configuration of HI-6 DMS in the dry chamber (500 mg +/- 25%) and 1 mL atropine (2 mg/mL) in the liquid chamber. The work will involve the following: • Project Management. • Analytical Method Development. • Material Processing and Performance Assessments. • Mixing and Drug Delivery Model. • Sterilization Impact Assessment.
What to check before bidding
- Issued by Department of National Defence (DND).
- Located in Canada.
- Source notice cb-357-41512202 on CanadaBuys.
- Notice published 2 Jun 2026; Tenqual indexed it 3 Jun 2026.
- Deadline listed as 16 Jun 2026.
- Create a free tender alert to catch similar opportunities before the deadline pressure starts.